Public procurement notice: Contract Notice
Published: 2020-10-06
Buyer: The NHS Commissioning Board (operating under the name of NHS England)
Country: UK
Contract type: Supplies
Procedure: Open procedure
CPV classification: 33600000: Pharmaceutical products
Estimated value: 754830788 GBP
Submission deadline: 2020-11-05
Award criteria: The most economic tender

Technical requirements: NHS Framework for the Midlands and East, Branded Medicines — Tranche B plus Cytokine Modulators and other Monoclonal Antibodies.
CM/PHR/20/5591/01 — Midlands and East, Branded Medicines — Tranche B. Period of framework: 1 March 2021 to 28 February 2023 with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.
CM/PHR/20/5591/02 — Midlands and East Branded Medicines — Annual Tranche, cytokine modulators, other monoclonal antibodies Interleukin Inhibitors, JAK Inhibitors and medicines for migraine and asthma. Period of framework: 1 March 2021 to 28 February 2022 with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months.
CM/PHR/20/5591/03 — Supply of Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma to Pan London. Period of framework: 1 March 2021 to 31 August 2021.
CM/PHR/20/5591/04 — Supply of Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma to South of England. Period of framework: 1 March 2021 to 31 August 2021.
CM/PHR/20/5591/04 — NHS Framework agreement for the supply of interleukin inhibitors, JAK inhibitors and medicines for migraine and asthma to South of England. Period of framework: 1 March 2021 to 31 August 2021.
CM/PHR/20/5591/03 — NHS Framework agreement for the supply of interleukin inhibitors, JAK inhibitors and medicines for migraine and asthma to Pan London. Period of framework: 1 March 2021 to 31 August 2021.
CM/PHR/20/5591/02 — NHS Framework for the Midlands and East Branded Medicines — annual tranche, cytokine modulators, other monoclonal antibodies interleukin inhibitors, JAK inhibitors and medicines for migraine and asthma. Period of framework: 1 March 2021 to 28 February 2022 with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months.
There will be an option to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months.
CM/PHR/20/5591/01 — NHS Framework for the Midlands and East, Branded Medicines — Tranche B. Period of framework: 1 March 2021 to 28 February 2023 with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.
There will be an option to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.
This procurement exercise will be conducted on the eTendering portal at https://health-family.force.com/s/Welcome Candidates wishing to be considered for this procurement exercise must register, and provide additional procurement specific information (if requested) through the eTendering portal as follows:
1.1) if not already registered, candidates should register on the eTendering portal at https://health-family.force.com/s/Welcome and click the link to register:
— select ‘Find Opportunities’ from the supplier home screen, use the ‘Sort by’: facility to find this opportunity and select the bold blue title to select,
— as you select the opportunity, you can review documents, send clarification messages, submit the response or decline to respond (if you decide not to participate in the opportunity);


Award value: 754830788